Logo Mark
Publications

Clinical Imetelstat: MF

All Publications

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Clinical Imetelstat: MFImetelstat
Frontiers in Oncology

Olschok, et. al.

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Clinical Imetelstat: MFImetelstat
ASH 2022

Mascarenhas, et al.

An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate-1, Intermediate-2 or High-Risk Myelofibrosis

Clinical Imetelstat: MFImetelstat
ASH 2022

Bradley T, et al.

Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design

Clinical Imetelstat: MFImetelstat
Future Oncology 2022

Mascarenhas, et al.

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data

Clinical Imetelstat: MFImetelstat
Annals of Hematology 2021

Kuykendall, et al.

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Clinical Imetelstat: MFImetelstat
Journal of Clinical Oncology 2021

Mascarenhas, et al.

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

Clinical Imetelstat: MFImetelstat
ASH 2020

Mascarenhas, et al.

Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase Inhibitor Treated with Imetelstat

Clinical Imetelstat: MFImetelstat
ASH 2020

Mascarenhas, et al.

Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Clinical Imetelstat: MFImetelstat
ASH 2020

Mascarenhas, et al.

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

Clinical Imetelstat: MFImetelstat
ASH 2020

Mascarenhas, et al.